Evolving Strategies in the Diagnosis and Management of Hemolytic Disease of the Fetus and Newborn

Evolving Strategies in the Diagnosis and Management of Hemolytic Disease of the Fetus and Newborn is organized by Global Academy for Medical Education  LLC.

Released:  11/18/2020
Valid until: 11/18/2021

CME Accreditation:
Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
Hemolytic disease of the fetus and newborn (HDFN) is a rare condition with an estimated 3 to 80 cases per 100,000 persons annually in the United States. Nonetheless, the complexity and increased risk for adverse outcomes in such cases requires more targeted approaches to HDFN that minimize or negate the risks associated with intrauterine transfusion.
This article focuses on the pathophysiology underlying fetal/newborn allo- and autoimmune diseases, especially HDFN and the current/evolving diagnostic and treatment regimens for HDFN.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Explain the pathophysiology underlying fetal/newborn allo- and autoimmune diseases, with a focus on HDFN.
• Identify current diagnostic and treatment regimens for HDFN.
• Explain the role of the neonatal Fc receptor pathway as a therapeutic means to address HDFN.